FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381377341> ?p ?o ?g. }

• W4381377341 abstract "Introduction: Post-prandial low blood glucose (LBG) is usually associated with late postprandial hyperinsulinemia in metabolic syndrome (MetS), but have not been well studied. Objectives: We aimed to 1) characterize insulin/glucose metabolism associated with LBG post 75g OGTT in a sample of individuals with MetS; and 2) assess the association between MAFLD (≥ 5% liver fat at MRI) and LBG. Methods: Plasma glucose, insulin and c-peptide concentrations were measured on OGTT over 180 mins. Insulin sensitivity and secretion were assessed with the Oral Minimal Model. During OGTT, we defined glucose ≤ 50 mg/dl as LBG, glucose &gt; 70 mg/dl as no LBG and glucose 51-70 mg/dl as undefined status and were excluded from this analysis. Results: Of 82 participants, 50 were included and 15 (18 %) experienced LBG. Of the 33 participants who underwent MRI, 48% had MAFLD. Median age and BMI were 59 [IQR: 49-74] years and 28 [IQR: 26-31] kg/m2 respectively. Women represented 70% (n=35) of participants and experienced less LBG (p=0.0002) than men. Individuals experiencing LBG had higher insulin sensitivity (p=0.02), higher ß cell function (p=0.03), earlier glucose peaks (p&lt;0.0001) and lower c-peptide peaks (p=0.007) than those without LBG. MAFLD was not associated with more LBG (p=0.7), but was associated with a different insulin curve. LBG+MAFLD status was associated with higher and later c-peptide and insulin levels compared to LBG without MAFLD status. Conclusion: In contrary to our hypothesis, individuals with MetS without MAFLD experiencing glucose ≤ 50 mg/dl during OGTT displayed a healthier metabolic profile. However, individuals with MAFLD experiencing a LBG during OGTT had a glucose phenotype similar to the late post-prandial hyperinsulinemic hypoglycemia often found in prediabetes state and associated with worst metabolic parameters. This suggests that MAFLD may be an important feature of MetS associated with a different post-OGTT glucose metabolism. Disclosure T.Gignac: None. A.Morissette: None. A.Agrinier: None. C.Gagnon: Advisory Panel; Novo Nordisk, Other Relationship; Ascendis Pharma A/S, Research Support; Novo Nordisk. M.Vohl: None. A.Marette: Advisory Panel; Valbiotis, Amancia, Plexus, Acasti. A.Carreau: Advisory Panel; Novartis, Consultant; Valbiotis, Speaker's Bureau; Novo Nordisk Canada Inc." @default.
• W4381377341 created "2023-06-21" @default.
• W4381377341 creator A5007768979 @default.
• W4381377341 creator A5008348962 @default.
• W4381377341 creator A5014659365 @default.
• W4381377341 creator A5084903539 @default.
• W4381377341 creator A5088671325 @default.
• W4381377341 creator A5091843056 @default.
• W4381377341 creator A5092215354 @default.
• W4381377341 date "2023-06-20" @default.
• W4381377341 modified "2023-09-25" @default.
• W4381377341 title "1586-P: Post-OGTT Low Blood Glucose in Individuals with Metabolic Syndrome, Metabolic Phenotypes, and Metabolic-Associated Fatty Liver Disease" @default.
• W4381377341 doi "https://doi.org/10.2337/db23-1586-p" @default.
• W4381377341 hasPublicationYear "2023" @default.
• W4381377341 type Work @default.
• W4381377341 citedByCount "0" @default.
• W4381377341 crossrefType "journal-article" @default.
• W4381377341 hasAuthorship W4381377341A5007768979 @default.
• W4381377341 hasAuthorship W4381377341A5008348962 @default.
• W4381377341 hasAuthorship W4381377341A5014659365 @default.
• W4381377341 hasAuthorship W4381377341A5084903539 @default.
• W4381377341 hasAuthorship W4381377341A5088671325 @default.
• W4381377341 hasAuthorship W4381377341A5091843056 @default.
• W4381377341 hasAuthorship W4381377341A5092215354 @default.
• W4381377341 hasConcept C126322002 @default.
• W4381377341 hasConcept C134018914 @default.
• W4381377341 hasConcept C17093226 @default.
• W4381377341 hasConcept C2777391703 @default.
• W4381377341 hasConcept C2778199505 @default.
• W4381377341 hasConcept C2778875212 @default.
• W4381377341 hasConcept C2779306644 @default.
• W4381377341 hasConcept C2780578515 @default.
• W4381377341 hasConcept C2780988686 @default.
• W4381377341 hasConcept C555293320 @default.
• W4381377341 hasConcept C71924100 @default.
• W4381377341 hasConceptScore W4381377341C126322002 @default.
• W4381377341 hasConceptScore W4381377341C134018914 @default.
• W4381377341 hasConceptScore W4381377341C17093226 @default.
• W4381377341 hasConceptScore W4381377341C2777391703 @default.
• W4381377341 hasConceptScore W4381377341C2778199505 @default.
• W4381377341 hasConceptScore W4381377341C2778875212 @default.
• W4381377341 hasConceptScore W4381377341C2779306644 @default.
• W4381377341 hasConceptScore W4381377341C2780578515 @default.
• W4381377341 hasConceptScore W4381377341C2780988686 @default.
• W4381377341 hasConceptScore W4381377341C555293320 @default.
• W4381377341 hasConceptScore W4381377341C71924100 @default.
• W4381377341 hasIssue "Supplement_1" @default.
• W4381377341 hasLocation W43813773411 @default.
• W4381377341 hasOpenAccess W4381377341 @default.
• W4381377341 hasPrimaryLocation W43813773411 @default.
• W4381377341 hasRelatedWork W138803513 @default.
• W4381377341 hasRelatedWork W1948194447 @default.
• W4381377341 hasRelatedWork W1986132654 @default.
• W4381377341 hasRelatedWork W2029210465 @default.
• W4381377341 hasRelatedWork W2044572938 @default.
• W4381377341 hasRelatedWork W2086423568 @default.
• W4381377341 hasRelatedWork W2129737421 @default.
• W4381377341 hasRelatedWork W2156708180 @default.
• W4381377341 hasRelatedWork W2418646588 @default.
• W4381377341 hasRelatedWork W2584731720 @default.
• W4381377341 hasVolume "72" @default.
• W4381377341 isParatext "false" @default.
• W4381377341 isRetracted "false" @default.
• W4381377341 workType "article" @default.